The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property

Sun, 15th Jun 2014 12:28

Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coffee. Some analysts fear Costa has reached saturation point but Barclays thinks Whitbread shares could rise from £42 to £70 as it starts to reap rewards from overseas investment. A second, cheaper hotel brand called Hub could also ease worries about growth prospects. The stock could pause for breath but it looks like a decent long-term bet.Buy Petra Diamonds, Questor recommended in the Sunday Telegraph. The shares are up 51% since Questor recommended them in September and following the discovery of a walnut-sized blue diamond the tipster is sticking by its opinion. The potential price Petra will receive for selling the gem could wipe out Petra's debt as it invests in upgrading its old mines. It has already said that production in the first nine months of its financial year was up 26%.Buy Empiric Student Property when it floats this week to tap into demand for more upmarket student housing, Midas advised in the Mail on Sunday. The management team will use £80m of the flotation proceeds to buy 11 properties to add to its existing fully occupied housing. In the UK's 27 top university cities, 96% of non-first years have no access to purpose-built housing. Many are prepared to pay to be near city centres, including 300,000 international students. Investors can expect a 6% dividend yield in the first year and capital growth as rents rise and development properties come into use.St Ives' shares have had a strong run and the media group is trading at levels not seen since before Lehman Brothers went bust in 2008, Matthew Goodman wrote in the Sunday Times. The company has transformed itself from printing books and annual reports into a media consultancy, advising on digital marketing and other things. St Ives has grown through acquisitions, leaving questions about its strategy, but its imminent trading update should reassure investors of the logic in its deals.Steer clear of PZ Cussons, the maker of Imperial Leather soap, Questor advised in the Sunday Telegraph. It is a quality company for the long term, withstanding recessions and rewarding investors through its dividend. But the shares are looking expensive, especially with growth slowing in Africa and Asia, where it makes about half its operating profits. Its expected annual profit would have been up to £12m higher without the impact of falling emerging markets currencies. Take some profit from Synairgen's success but do not sell out of the biotech company entirely, Midas said in the Mail on Sunday. The shares jumped by 20p to 70p last week when Synairgen signed a $238m deal with AstraZeneca for Astra to develop and sell its treatment to help asthma and emphysema sufferers who have a cold or flu. Midas recommended the shares at 28p in January 2010 and at 39p two years ago. There is plenty more upside for investors when the potential blockbuster drug goes on sale in a few years.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.SF
More News
6 Jan 2022 14:51

IN BRIEF: Synairgen signs partnership for its Covid-19 treatment in US

IN BRIEF: Synairgen signs partnership for its Covid-19 treatment in US

Read more
11 Nov 2021 18:36

TRADING UPDATES: Avation sells Airbus jet; Mode Global's bitcoin deal

TRADING UPDATES: Avation sells Airbus jet; Mode Global's bitcoin deal

Read more
11 Nov 2021 13:03

Synairgen secures patients for phase III study of Covid treatment, shares jump

(Sharecast News) - Shares in Synairgen rallied on Thursday,after the respiratory drug specialist confirmed it was starting a Phase III study into a potential Covid-19 treatment.

Read more
20 Oct 2021 11:14

IN BRIEF: Synairgen Covid treatment pushed for phase 3 trials by Activ

IN BRIEF: Synairgen Covid treatment pushed for phase 3 trials by Activ

Read more
20 Oct 2021 10:56

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

Read more
30 Sep 2021 14:42

EARNINGS UPDATES: President Energy slims loss; Jangada turns a profit

EARNINGS UPDATES: President Energy slims loss; Jangada turns a profit

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
11 Jun 2021 15:59

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 May 2021 12:02

TRADING UPDATES: Digital 9 raises cash; Bluejay and Rio start drilling

TRADING UPDATES: Digital 9 raises cash; Bluejay and Rio start drilling

Read more
24 May 2021 08:33

Synairgen drug proves effective against Covid variants in lab tests

(Sharecast News) - A drug being developed by Synairgen to treat severe lung infections has shown promising laboratory results against emerging variants of Covid-19, the biotech announced on Monday.

Read more
12 May 2021 14:26

TRADING UPDATES: Vertu Motors profit jumps; Mears swings to 2020 loss

TRADING UPDATES: Vertu Motors profit jumps; Mears swings to 2020 loss

Read more
30 Apr 2021 14:15

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

Read more
15 Feb 2021 11:57

Synairgen confirms start of dosing in Covid-19 trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Monday that dosing has started in the inhaled interferon beta formulation 'SNG001' sub-study of the 'ACTIV-2' phase 2 and 3 trial, evaluating patients with mild-to-moderate Covid-19 symptoms not yet requiring hospitalisation.

Read more
15 Feb 2021 10:52

IN BRIEF: Synairgen Begins Dosing Of Covid Patients In SNG001 Sub-Study

IN BRIEF: Synairgen Begins Dosing Of Covid Patients In SNG001 Sub-Study

Read more
25 Jan 2021 19:18

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.